Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We characterized a prospective endometrial carcinoma (EC) cohort containing 138 tumors and 20 enriched normal tissues using 10 different omics platforms. Targeted quantitation of two peptides can predict antigen processing and presentation machinery activity, and may inform patient selection for immunotherapy. Association analysis between MYC activity and metformin treatment in both patients and cell lines suggests a potential role for metformin treatment in non-diabetic patients with elevated MYC activity. PIK3R1 in-frame indels are associated with elevated AKT phosphorylation and increased sensitivity to AKT inhibitors. CTNNB1 hotspot mutations are concentrated near phosphorylation sites mediating pS45-induced degradation of β-catenin, which may render Wnt-FZD antagonists ineffective. Deep learning accurately predicts EC subtypes and mutations from histopathology images, which may be useful for rapid diagnosis. Overall, this study identified molecular and imaging markers that can be further investigated to guide patient stratification for more precise treatment of EC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631452 | PMC |
| http://dx.doi.org/10.1016/j.ccell.2023.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.
Int J Clin Oncol
September 2025
Department of Obstetrics and Gynecology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.
View Article and Find Full Text PDFDelineating the clinico-oncological landscape: Pure Uterine Serous Cancer (P-USC) versus p53 Abnormal Grade 3-Endometrioid-Endometrial Carcinoma (p53 Abn G3-EEC).
Eur J Obstet Gynecol Reprod Biol
September 2025
Department of Biostatistics, Amrita Institute of Medical Sciences, Ponekkara Rd, Edappally, Kochi, Ernakulam 682041 Kerala, India.
Objective: This study compared the oncological outcomes of Pure Uterine Serous Carcinomas (p-USC) and p53-Abnormal Grade 3 Endometroid Endometrial Tumours (p53 Abn G3-EEC).
Methods: A retrospective study was conducted at Amrita Institute of Medical Sciences from February 1, 2015, to December 31, 2020, analysing patients diagnosed with P-USC and p53 Abn G3-EEC. The primary objective was to compare the 5-year Progression-Free Survival (PFS) between two groups.
Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.
Gynecol Oncol
September 2025
Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Objective: This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.
Methods: In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.
Results: We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.
Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.
Gynecol Oncol
September 2025
University of Chicago, Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Chicago, IL 60637, USA; University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL 60637, USA.
Objective: To identify associations between race, neighborhood disadvantage, and outcomes in women with stage I-III endometrioid endometrial cancer (EEC) treated at a tertiary referral center.
Methods: This retrospective tumor registry study included patients with stage I-III EEC between 1/2006 and 12/2022. Progression-free (PFS) and overall survival (OS) were analyzed by race and neighborhood disadvantage, stratified by Area Deprivation Index (ADI; national quartile).
Advanced robotic surgery in obese patients with gynecological cancers: tips and tricks from literature to clinical practice.
J Robot Surg
September 2025
Department of Gynecology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Obesity is closely linked to an increased incidence of several gynecological conditions and poses significant challenges to their surgical management. Among these, endometrial cancer stands out due to its high prevalence in patients with elevated body mass index, with nearly 60% of those requiring primary surgical treatment classified as obese or morbidly obese. The coexistence of multiple comorbidities in this population contributes to a heightened risk of perioperative and postoperative complications.
View Article and Find Full Text PDF